Direct Healthcare Professional Communication: Expected shortage of guanfacine hydrochloride (Intuniv) prolonged-release tablets
Letter includes dates of expected supply disruptions of the prolonged-release tablets. For existing patients, healthcare professionals will need to decide on an appropriate course of action based on the individual clinical situation and their own clinical judgement.
Source:
Takeda
SPS commentary:
A National Patient Safety Alert (NatPSA/2023/011/DHSC) was issued on 27 September 2023 outlining supply disruptions affecting methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets, and providing further background and clinical information and actions for providers.